top of page
SEYLTX
Pipeline
Phase 1
Prevalence
Phase 2b
Disease
Program
Phase 2a
3,000: 100,000
Refractory Chronic Cough (RCC)
SEY-101
IPF-RCC
SEY-201
13-20: 100,000
The FDA has accepted our safety and Phase 2a data to support entering Phase 2b
bottom of page